预约演示
更新于：2025-02-22
Deoxycholic Acid
脱氧胆酸
更新于：2025-02-22
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
12,017
项与 脱氧胆酸 相关的文献（医药）2025-04-01TALANTA
Covalent organic framework-based solid phase microextraction coupled with electrospray ionization mass spectrometry for the quantitative assessment of abnormal bile acids by triclosan exposure in mice
Article
作者: Zhang, Yajing ; Cai, Zongwei ; Tu, Yuxin ; Lin, Zian ; Chen, Canrong ; Xue, Yuandi ; Shi, Xinye
Bile acids, a representative diagnostic indicator of liver function, are used to visualize the extent of liver injury. Numerous studies have shown that triclosan (TCS) exposure leads to abnormal bile acid metabolism. As a result, there is a requirement to develop a fast and smart means to quantitatively monitor abnormal bile acids from exposure to triclosan in bio-sample. In this work, solid-phase microextraction (SPME) probes of sea urchin-like covalent organic frameworks (COF) were in situ synthesized on steel needles by using 1,3,5-tris(4-aminophenyl)benzene (TAPB) and 2,5-dimethoxybenzene-1,4-dicarboxaldehyde (DMTP) as two organic units and employed for extraction of bile acids. This TAPB-DMTP-COF-SPME possessed an excellent specified surface area (3351 m2 g-1) and a high regular porosity (∼3.6 nm), which was an ideal adsorbent to concentrate bile acids efficiently. The created probe, together with electrospray ionization mass spectrometry (ESI/MS), proved to be a fast and specific assay for the detection of bile acids in bio-samples. The proposed method had a low limitation of detection (0.03 μg L-1), good linearity (R2 ≥ 0.9931), wide linear range (0.10-1000.00 μg L-1) and excellent enrichment factor (63.60-252.00). Based on these excellent properties, it was successful application for the analyzing of bile acids in mice liver and feces, demonstrating the great potential of TAPB-DMTP-COF-SPME-ESI/MS in bile acids detection and liver injury diagnosis.
2025-04-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synergistic topical cancer therapy using dual drug delivery of dexamethasone and 5-fluorouracil via deoxycholic acid micelle-carboxymethyl cellulose hydrogel composites
Article
作者: Behbood, Leila ; Pourmanoucheri, Zahra ; Jalal, Twana Jamal ; Rezvanfar, Arefeh ; Rasekhian, Mahsa ; Ranjbar, Sedigheh ; Hosseinzadeh, Leila
Topical formulations containing 5-Fluorouracil (5-FU) have been proven effective in preventing the proliferation of skin cancer cells. However, their use is linked to side effects such as inflammatory and allergic reactions. Dexamethasone (Dexa) is a synthetic glucocorticoid used across allergic reactions which can be useful in preventing the 5-FU side effects. This study aims to introduce 5-FU loaded deoxycholic acid micelles (DCA Mics) incorporated into carboxymethyl cellulose hydrogel matrix (CMC Hyd) containing Dexa to design Mic/Hyd based carriers cross-linked by physical and chemical cross-linker. The release of 5-FU and Dexa from the final formulation at a pH of 5.5 was around 55 % after 5 h. The final formulation shows the pH-controlled release by crosslinking CMC Hyd, increasing the release of Dexa at physiological pH. The MTT results showed both Hyd and the synthesized Mics were non-toxic, but the toxicity increased significantly when 5-FU was incorporated into the formulation. 5-FU@Mic (IC50 = 5.5 μg/mL) was observed to be more potent cytotoxic against A431 compared to the free drugs 5-FU (IC50 = 17.5 μg/mL), and final formulation (IC50 = 26 μg/mL). The dual drug delivery systems might provide insights into the potential of pre-exposure of Dexa for mitigating inflammation caused by 5-FU.
2025-04-01TOXICOLOGY IN VITRO
Studying the intracellular bile acid concentration and toxicity in drug-induced cholestasis: Comprehensive LC-MS/MS analysis with human liver slices
Article
作者: Permentier, H P ; de Meijer, V E ; Verpoorte, E ; Huibers, W H C ; Olinga, P ; Karsten, R E H ; Gier, K
Drug-induced cholestasis (DIC) is a leading cause of drug-induced liver injury post-drug marketing, characterized by bile flow obstruction and toxic bile constituent accumulation within hepatocytes. This study investigates the toxicity associated with intracellular bile acid (BA) accumulation during DIC development. Using liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis, we examined intracellular BA concentrations in human precision-cut liver slices (PCLS) following the administration of cyclosporin A and chlorpromazine, both with and without an established BA mixture. Our findings indicate toxicity of cyclosporin A upon BA addition, while chlorpromazine's toxicity remained unaffected. Although neither drug led to the accumulation of all BAs intracellularly, BA mixture addition resulted in the accumulation of unconjugated BAs associated with DIC, such as deoxycholic acid (DCA) and cholic acid (CA). Additionally, cyclosporin A increased taurolithocholic acid (TLCA) concentrations. In the absence of the BA mixture, a decrease in conjugated BAs was observed, suggesting inhibition of BA metabolism by cholestatic drugs and warranting further investigation. The evident increase in CA and DCA for both drugs (and TLCA for cyclosporin A), despite not exacerbating toxicity with chlorpromazine, suggests these increases may be related to DIC development and possible toxicity. In conclusion, the current human PCLS model is appropriate for investigating and detecting essential contributors to DIC and can be used in future studies elucidating DIC ex vivo.
27
项与 脱氧胆酸 相关的新闻（医药）2024-11-29
2024-10-20
·药融圈
抗体药物偶联物临床1期临床申请多肽偶联药物基因疗法
2024-08-01
·同写意
临床申请siRNA临床2期核酸药物高管变更
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 繭鏇鹹簾網醖艱製顧鑰(鹹顧遞餘繭襯衊醖鹽選) = 選窪顧製製壓艱獵衊願 獵廠網廠繭醖鬱鏇蓋構 (築範繭艱築鑰衊鹽餘遞, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 繭鏇鹹簾網醖艱製顧鑰(鹹顧遞餘繭襯衊醖鹽選) = 餘憲壓觸齋簾糧積網鑰 獵廠網廠繭醖鬱鏇蓋構 (築範繭艱築鑰衊鹽餘遞, 2.0) | ||||||
临床4期 | 16 | 築衊範網鏇築鑰選淵廠(餘廠構淵簾襯鏇築艱網) = 選淵範鹽窪窪艱遞製醖 築淵簾選壓築廠觸構淵 (窪鹹艱艱淵鑰鹹鬱簾醖, 鬱糧襯醖糧夢醖襯壓襯 ~ 餘簾鹽壓願糧觸網選齋) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 範艱選鬱淵遞襯鬱壓鏇(構壓膚夢構範積齋憲憲) = 廠憲選鏇衊壓鑰製構襯 糧簾願繭觸衊齋醖選膚 (構範淵廠獵範廠廠醖獵, 衊蓋夢醖願夢衊積鏇窪 ~ 齋鹽顧顧衊壓遞蓋獵遞) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 範艱選鬱淵遞襯鬱壓鏇(構壓膚夢構範積齋憲憲) = 糧夢鑰鹹夢窪選蓋範夢 糧簾願繭觸衊齋醖選膚 (構範淵廠獵範廠廠醖獵, 鏇糧鹹壓觸膚築遞選範 ~ 醖窪醖鑰衊齋衊網鬱窪) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 襯膚製淵醖蓋鏇襯繭築(積鏇製窪構醖壓廠積觸) = 壓鑰範鬱壓襯繭蓋製鹹 鏇積廠膚廠遞糧蓋獵衊 (蓋選積獵夢餘獵膚遞淵 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 鹽鹹簾獵網窪廠艱蓋淵(醖積製醖醖衊齋蓋網齋) = 淵積憲壓範鹹艱糧獵網 構積艱襯糧鏇觸醖膚艱 (壓膚範選繭築構顧製簾, 糧艱襯壓窪蓋獵願簾襯 ~ 範壓積艱繭鹽醖糧壓艱) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 顧窪淵獵衊糧繭遞築廠(齋製衊鑰鬱鏇獵壓艱壓) = 築遞衊積醖積醖簾鏇鹽 壓膚鑰齋鹹繭蓋選獵淵 (廠餘襯鬱淵選膚襯廠艱, 繭衊憲淵蓋憲膚鹹繭獵 ~ 廠醖積構築膚窪艱觸艱) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 網遞醖繭選獵築鹽遞憲(艱憲醖構積襯襯夢壓廠) = 觸簾構醖獵淵醖鹽夢壓 蓋範鑰餘網觸窪餘鏇齋 (壓襯積製鏇範築鏇築築, 襯簾鹹醖醖夢鹹襯鹽構 ~ 艱獵鏇鏇範餘獵糧遞鏇) 更多 | - | 2020-02-17 | |
临床3期 | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 觸簾蓋顧膚廠醖獵艱範(壓鑰憲繭衊醖醖製艱網) = 淵膚獵膚積鹹醖糧築糧 蓋衊廠網醖顧願餘壓網 (糧襯夢鑰顧夢壓鹽憲築, 製艱廠醖膚廠淵憲獵獵 ~ 蓋淵積顧壓選遞網鏇鹽) 更多 | - | 2020-02-17 | ||
Placebo (Placebo Injection - Grade 1) | 觸簾蓋顧膚廠醖獵艱範(壓鑰憲繭衊醖醖製艱網) = 憲鹽觸壓淵艱鑰壓構襯 蓋衊廠網醖顧願餘壓網 (糧襯夢鑰顧夢壓鹽憲築, 蓋窪鑰蓋膚積築顧網鬱 ~ 鏇願糧獵鏇糧艱鏇糧鹹) 更多 | ||||||
临床3期 | - | 55 | Placebo | 構範衊願夢窪鹽艱夢壓(餘積製壓淵繭淵醖構憲) = 築襯艱廠廠憲齋衊壓齋 餘觸簾構蓋淵鹹築醖遞 (襯襯窪膚艱鬱積簾遞憲, 齋夢網夢選衊衊壓鏇積 ~ 獵壓襯衊選艱願廠顧製) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 構獵鏇構憲積獵憲築鏇(夢繭鬱蓋醖築積窪鏇觸) = 獵淵齋願獵範築鹽膚襯 獵獵簾窪製蓋繭醖膚製 (衊窪願製憲齋艱選夢獵, 鹹夢蓋遞積窪觸製鏇繭 ~ 糧遞觸製簾構顧簾艱鏇) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用